- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Dulaglutide may prevent weight gain after quitting smoking especially among women: BMJ
Researchers have found in a new study that Dulaglutide reduced postcessation weight gain in both genders and was very effective in preventing substantial weight gain.
Further the researchers Dr Fabienne Baur and team discovered that women face greater challenges in quitting smoking compared to men.
The findings of the study were published in the BMJ Nutrition.
The findings from this double-blind, placebo-controlled, randomized trial included 255 daily smokers revealed a concerning trend. The research involved 155 women and 100 men with weekly doses of dulaglutide (1.5 mg) or a placebo alongside standard smoking cessation care over a 12-week period. The smoking cessation care consisted of varenicline (2 mg/day) with behavioral counseling.
This study found no significant sex differences in absolute or relative weight change for those on dulaglutide or placebo treatments. However, a big contrast emerged regarding substantial weight gain that was defined as over a 6% increase. In the placebo group, women (24%) experienced almost five times more substantial weight gain than men (5%).
The outcome with dulaglutide intervention showed its effectiveness in reducing post-cessation weight gain in both genders. The female participants were notably less likely to experience substantial weight gain on dulaglutide (1%) when compared to the placebo (24%). Although the dulaglutide effect was less pronounced in men it still demonstrated effectiveness in preventing substantial weight gain.
This study indicates that dulaglutide could be a potential agent in assisting women and men in overcoming the hurdle of weight gain which is associated with quitting smoking. As smoking-related diseases disproportionately affect women, this intervention could mark an important stride towards addressing sex-specific challenges in smoking cessation that could possibly help to tailored treatments for a healthier, smoke-free future.
Reference:
Baur, F., Atila, C., Lengsfeld, S., Burkard, T., Meienberg, A., Bathelt, C., Christ-Crain, M., & Winzeler, B. (2023). Gender differences in weight gain during attempted and successful smoking cessation on dulaglutide treatment: a predefined secondary analysis of a randomised trial. In BMJ Nutrition, Prevention & Health (p. e000781). BMJ. https://doi.org/10.1136/bmjnph-2023-000781
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in